Browse
Submit Data
Databases
API
Help

Dataset Information

4 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MiR-522 IMPACT-seq in MDA-MB-468

ABSTRACT: Identifying miRNA-regulated genes is key to understanding miRNA function. However, many miRNA recognition elements (MREs) do not follow canonical seed base-pairing rules, making identification of bona fide targets challenging. Here, we apply an unbiased sequencing-based systems approach to characterize miR-522, a member of the oncogenic primate-specific chromosome 19 miRNA cluster, highly expressed in poorly differentiated cancers. To identify miRNA targets, we sequenced full-length transcripts captured by a biotinylated miRNA mimic. Within these targets, mostly non-canonical MREs were identified by sequencing RNase-resistant fragments (this dataset).

ORGANISM(S): Homo sapiens

SUBMITTER: Tan Shen Mynn

PROVIDER: S-ECPF-MTAB-2119 | biostudies-other |

REPOSITORIES: biostudies-other

ACCESS DATA

Json Xml

Similar Datasets

miR-522 IMPACT-seq in MDA-MB-468

Project description:Identifying miRNA-regulated genes is key to understanding miRNA function. However, many miRNA recognition elements (MREs) do not follow canonical seed base-pairing rules, making identification of bona fide targets challenging. Here, we apply an unbiased sequencing-based systems approach to characterize miR-522, a member of the oncogenic primate-specific chromosome 19 miRNA cluster, highly expressed in poorly differentiated cancers. To identify miRNA targets, we sequenced full-length transcripts captured by a biotinylated miRNA mimic. Within these targets, mostly non-canonical MREs were identified by sequencing RNase-resistant fragments (this dataset).

2014-06-03 | E-MTAB-2119 | biostudies-arrayexpress

miR-522 IMPACT-seq in MDA-MB-468

Project description:miR-522 IMPACT-seq in MDA-MB-468

| PRJEB5041 | ENA

miR-522 Pulldown-seq in MDA-MB-468

Project description:Identifying miRNA-regulated genes is key to understanding miRNA function. However, many miRNA recognition elements (MREs) do not follow canonical seed base-pairing rules, making identification of bona fide targets challenging. Here, we apply an unbiased sequencing-based systems approach to characterize miR-522, a member of the oncogenic primate-specific chromosome 19 miRNA cluster, highly expressed in poorly differentiated cancers. To identify miRNA targets, we sequenced full-length transcripts captured by a biotinylated miRNA mimic (this dataset). Within these targets, mostly non-canonical MREs were identified by sequencing RNase-resistant fragments.

2014-06-03 | E-MTAB-2112 | biostudies-arrayexpress

RNA-seq of coding and non-coding RNA from miR-522 pulldown in human MDA-MB-468 breast cancer cells

Project description: Not available

| S-ECPF-MTAB-2112 | biostudies-other

Transcription profiling of human rapamycin treated of MDA-MB-468 breast cancer cell line and MDA-MB-468 xenografts

Project description: Not available

| S-ECPF-GEOD-18571 | biostudies-other

miR-522 Overexpression in MDA-MB-468

Project description:Over-expression of miR-522 mimic or control miR mimic in MDA-MB-468 breast cancer cell line

2014-06-30 | E-MTAB-2110 | biostudies-arrayexpress

ALDH1A3-mediated gene expression in MDA-MB-231 cells and MDA-MB-468 cells

Project description: Not available

| S-ECPF-GEOD-49322 | biostudies-other

miR-522 Pulldown-seq in MDA-MB-468

Project description:miR-522 Pulldown-seq in MDA-MB-468

| PRJEB5038 | ENA

Overexpressing modified human TR?1 suppresses the proliferation of breast cancer MDA-MB-468 cells.

Project description: Not available

| S-EPMC6019938 | biostudies-literature

Rapamycin treatment of MDA-MB-468 breast cancer cell line and MDA-MB-468 xenografts

Project description:Mammalian target of rapamycin (mTOR) is a serine/threonine kinase involved in multiple intracellular signaling pathways promoting tumor growth. mTOR is aberrantly activated in a significant portion of breast cancers and is a promising target for treatment. Rapamycin and its analogues are in clinical trials for breast cancer treatment. Patterns of gene expression (metagenes) may also be used to simulate a biologic process of effects of a drug treatment. In this study, we tested the hypothesis that the gene-expression signature regulated by rapamycin could predict disease outcome for patients with breast cancer. Results: Colony formation and sulforhodamine B (IC50 < 1nM) assays, and xenograft animals showed that MDA-MB-468 cells were sensitive to treatment with rapamycin. The comparison of in vitro and in vivo gene expression data identified a signature, termed rapamycin metagene index (RMI), of 31 genes upregulated by rapamycin treatment in vitro as well as in vivo (false discovery rate of 10%). In the Miller dataset, RMI was significantly associated with tumor size or lymph node status. High (>75) percentile) RMI was significantly associated with longer survival (P = 0.015). On multivariate analysis, RMI (P = 0.029), tumor size (P = 0.015) and lymph node status (P = 0.01) were prognostic. In van 't Veer study, RMI was not associated with the time to develop distant metastasis (P = 0.41). In Wang dataset, RMI predicted time to disease relapse (P = 0.09). Conclusions: Rapamycin-regulated gene expression signature predicts clinical outcome in breast cancer. This supports the central role of mTOR signaling in breast cancer biology and provides further impetus to pursue mTOR-targeted therapies for breast cancer treatment. Mol Cancer. 2009 Sep 24;8(1):75.

2009-11-20 | GSE18571 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data